Hispanic race and amount of healthcare resource utilization may h

Hispanic race and amount of healthcare resource utilization may have a role in explaining this variation.

Table 1. Regional data regarding THC, length of stay and number of procedures for inpatients with AH (n=11,304) *denotes significantly greater result relative to other regions (p<0.05) Disclosures: Ashwini Lakshmanan - Advisory Committees or Review Panels: Salix Pharmaceuticals Vinay Sundaram - Advisory Committees or Review Panels: Salix, Gilead, Jansen; Speaking and Teaching: Salix The following people have nothing to disclose: Folasade P. May, Vineet Syan BACKGROUND AND AIM: New interferon-free regimens for treatment of CHC have high efficacy and favorable safety profile. Our aim was to Cabozantinib assess PROs in CHC with different stages of hepatic fibrosis treated with SOF+LDV regimens. METHODS: PRO questionnaires [Chronic Liver Disease Questionnaire-HCV (CLDQ-HCV), Short Form-36 (SF-36), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), and Work Productivity and Activity Index: Specific Health Problem (WPAI:SHP)] were administered at baseline, during, and post-treatment to genotype 1 CH-C subjects

treated with SOF+LDV+RBV or SOF+LDV for 8, 12 and 24 weeks (ION-1, 2 and 3 clinical trials). METAVIR fibrosis stage was determined from pretreatment liver biopsies. RESULTS: 1,005 subjects who had undergone liver biopsies were included (94 – stage 0 fibrosis, 311 – stage 1, 301 – stage 2, 197 – this website stage 3, and 102 – stage 4). Patients with earlier stages of fibrosis were younger (p=0.0043) with lower BMI (p=0.0015) and lower ALT (p<0.0001). At baseline, patients with more advanced fibrosis had greater PRO impairments; this difference was most prominent for PROs related to physical functioning Tideglusib including the physical component of SF-36, physical and emotional well-being and fatigue scale of FACIT-F, activity impairment of WPAI:SHP (up to 12.6% less impairment in stage 0 vs. stage 4, p<0.0001). In multivariate analysis, the stage of fibrosis was independently associated with impairment of PROs (CLDQ-HCV, physical component of SF-36, total FACIT-F and activity impairment

of WPAI scores: beta up to -2.4% per each additional stage, p<0.05). During and post-treatment, these PROs remained lower in patients with advanced fibrosis. Nevertheless, significant improvements (p<0.05) in most PROs were observed at SVR-12, regardless of fibrosis stage (by 2.4%-10.3% from baseline; all p>0.05 across fibrosis stages). In particular, patients with stages 0-2 (early fibrosis) had similar PRO improvements as compared to those with advanced fibrosis [e.g., improvement in vitality of SF-36 from baseline: +7.94% in stages 0-2 (p<0.0001), +8.08% in stages 3-4 (p<0.0001), (p>0.05 between fibrosis groups)]. In multivariate analysis, improvement of PROs after SVR-12 was not related to the stage of fibrosis (all p>0.05).

Comments are closed.